|Mr. Richard W. Pascoe||Chief Exec. Officer, Principal Accounting Officer, Sec. and Director||500.23k||N/A||54|
|Mr. Brian T. Dorsey||Chief Devel. Officer and Sr. VP||331.89k||N/A||49|
|Mr. Neil C. Morton||Chief Bus. Officer and Sr. VP||286.81k||N/A||42|
|Ms. Kelly Deck||Exec. Director of Fin.||N/A||N/A||N/A|
|Ms. Mary Naggs||VP and Gen. Counsel||N/A||N/A||N/A|
Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company also engages in developing RayVa, which is in Phase 2 development for the treatment of Raynaud's Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Apricus Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.